Boston Therapeutics Inc (BTHE) financial statements (2021 and earlier)

Company profile

Business Address 354 MERRIMACK STREET
LAWRENCE, MA 01843
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 71213768741157
Cash and cash equivalents 71213768741157
Receivables  015  
Inventory, net of allowances, customer advances and progress billings 413955110198
Inventory 413955110198
Prepaid expense     7889
Other undisclosed current assets 1390821583  
Total current assets: 23922391830229445
Noncurrent Assets
Property, plant and equipment 1242814
Intangible assets, net (including goodwill)  515509573638702
Goodwill   70707070
Intangible assets, net (excluding goodwill)  515439504568632
Other undisclosed noncurrent assets     42
Total noncurrent assets: 1517513575649718
TOTAL ASSETS: 241,4399041,4058781,163
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 1,0981,670652667853772
Accounts payable 458510299319575411
Accrued liabilities 2,4591,161353347278278
Interest and dividends payable      83
Other undisclosed accounts payable and accrued liabilities (1,819)     
Debt 7004501,207   
Derivative instruments and hedges, liabilities 954429   
Due to related parties 2,10175827829820 
Other liabilities      63
Other undisclosed current liabilities 3,7881,7261,122112164(44)
Total current liabilities: 7,6964,6593,6881,0771,038791
Noncurrent Liabilities
Long-term debt and lease obligation    36593 
Long-term debt, excluding current maturities    36593 
Liabilities, other than long-term debt     278298
Due to related parties     278298
Other undisclosed noncurrent liabilities  9261,0993,082  
Total noncurrent liabilities:  9261,0993,447371298
Total liabilities: 7,6965,5854,7874,5241,4091,088
Stockholders' equity
Stockholders' equity attributable to parent, including: (7,672)(4,146)(3,884)(3,119)(531)75
Preferred stock  00   
Common stock 11111064473939
Additional paid in capital 19,32319,15615,86315,06113,71912,035
Accumulated deficit (27,106)(23,412)(19,811)(18,226)(14,489)(11,999)
Other undisclosed stockholders' equity attributable to parent 0   200 
Total stockholders' equity: (7,672)(4,146)(3,884)(3,119)(531)75
TOTAL LIABILITIES AND EQUITY: 241,4399041,4058781,163

Income statement (P&L) ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues 1632299999200
Revenue, net7 70182
Cost of revenue
(Cost of Goods and Services Sold)
  (32)(13)(94)(240)(176)
Gross profit: 16(0)165(142)24
Operating expenses (3,877)(3,311)(1,295)(1,269)(1,960)(4,698)
Other undisclosed operating income  3213   
Operating loss: (3,860)(3,279)(1,266)(1,264)(2,101)(4,674)
Nonoperating expense    (402)(4)(6)
Other nonoperating expense    (402)(4)(5)
Interest and debt expense (343)2(1,738)(1,943)(311)(20)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes 509(324)1,419(125)  
Loss from continuing operations before income taxes: (3,694)(3,601)(1,585)(3,734)(2,416)(4,700)
Income tax expense    (4)  
Loss before gain (loss) on sale of properties: (3,694)(3,601)(1,585)(3,738)(2,416)(4,700)
Other undisclosed net loss     (73) 
Net loss available to common stockholders, diluted: (3,694)(3,601)(1,585)(3,738)(2,490)(4,700)

Comprehensive Income ($ in thousands)

9/30/2020
TTM
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss: (3,694)(3,601)(1,585)(3,738)(2,490)(4,700)
Comprehensive loss, net of tax, attributable to parent: (3,694)(3,601)(1,585)(3,738)(2,490)(4,700)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: